4.5 Article

Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: Implications for phenotyping

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jchromb.2007.11.030

关键词

methylphenidate; esterase; pharmacogenetics; enantiomers; urine

资金

  1. NCRR NIH HHS [M01 RR01070, M01 RR001070, M01 RR001070-280360] Funding Source: Medline
  2. NIAAA NIH HHS [R01 AA016707-03A1, R01 AA016707, R01AA016707] Funding Source: Medline
  3. NIDA NIH HHS [R01DA-15797, R01 DA015797] Funding Source: Medline

向作者/读者索取更多资源

A chiral derivatization gas chromatographic-mass spectrometric (GC-MS) method for urine methylphenidate (MPH) analysis was developed and validated to investigate preliminary findings regarding a novel MPH poor metabolizer (PM). Detection was by electron impact (EI) ionization-selected ion monitoring of the N-trifluoroacetylprolylpiperidinium fragments from MPH and the piperidine-deuterated MPH internal standard. The PM eliminated similar to 70 times more 1-MPH in urine (9% of the dose over 0-10 h), and similar to 5 times more of the d-isomer (10% of the dose), than the mean values determined from 10 normal metabolizers of MPH. Only minor amounts of the metabolite p-hydroxy-MPH were found in the urine of both the PM and normal metabolizers, while the concentration of MPH lactam was not high enough to be detectable. The described method indirectly gauges the functional carboxylesterase-1 status of patients receiving MPH based on the evaluation of relative urine concentrations of d-MPH:1-NWH. Clinical implications concerning rational drug selection for an identified or suspected MPH PM are discussed. (c) 2007 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据